Compare Delta Air Lines, Inc. (DAL) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Delta Air Lines, Inc. vs Revvity Inc — how do they compare? Delta Air Lines, Inc. trades at $83.23 (market cap $54.56B), while Revvity Inc trades at $152.05 (market cap $17.14B). The key difference: Delta Air Lines, Inc. is far larger — about 3.2× Revvity Inc's market cap, and Delta Air Lines, Inc. pays the higher dividend (1.04%). Which is the better fit depends on your goals — on Pluang, investors hold Delta Air Lines, Inc. for 97 Days and Revvity Inc for 12 Days on average.
| DAL | RVTY | |
|---|---|---|
Market Cap | $54.56B | $17.14B |
Volume | 6,532,736 | 2,226,396 |
Sector | Industrials | Health |
52-Week High | $93.66 | $157.36 |
52-Week Low | $55.65 | $82.26 |
Typical Hold Time | 97 Days | 12 Days |
Enterprise Value | $69.88B | $19.46B |
Dividend Yield | 1.04% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Delta Air Lines (DAL) trades at $82.97, down 0.82% on the day, with technical indicators showing bearish momentum despite strong fundamentals. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue growth has been steady, reaching $63.36 billion in 2025, while profitability metrics remain solid with a 5.78% net income margin and 20.12% ROE. Analyst sentiment remains overwhelmingly positive with 82% buy ratings and a $103.36 consensus price target representing 25% upside potential.
DAL presents a compelling investment case with attractive valuation multiples (P/E of 13.76, P/S of 0.8) and strong cash flow generation, though near-term headwinds include fuel cost volatility and competitive pressures. The stock's technical weakness contrasts with fundamental strength, creating potential opportunity for patient investors. Key risks include oil price sensitivity and execution challenges in maintaining premium customer loyalty against aggressive competitor tactics.
RVTY trades at $153.60, up 0.2% today and near its 52-week high of $158.28. The stock shows bullish technical momentum with consistent earnings beats in recent quarters. Recent developments include the launch of a new diabetes detection kit in Europe and the acquisition of Human Cell Design to expand metabolic disease research capabilities. Operating cash flow improved to $628 million in 2026 from $583 million in 2025.
RVTY presents growth potential through diagnostic expansion and AI-driven demand, though premium valuation metrics pose near-term risks. The company faces margin pressures in China and competitive challenges. With 52% analyst buy ratings and strong institutional interest, the stock offers upside to the $165 high target but requires monitoring of Q3 earnings due November 3.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Delta Air Lines, Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Read more on DAL →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
